Annals of Oncology 13:1460-1468, 2002
© 2002 European Society for Medical Oncology
Original Paper |
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie
1 Departments of Biostatistics and Medicine, Centre Léon Bérard, Lyon; 2 Department of Medicine, Institut Gustave Roussy, Villejuif; 3 Department of Medicine, Centre René Gauducheau, Nantes; 4 Department of Medicine, Institut Bergonié, Bordeaux; 5 Department of Medicine, Centre Claudius Regaud, Toulouse, France
Received 19 November 2001; revised 2 April 2002; accepted 11 April 2002
Interleukin-2 (IL-2) or/and interferon (IFN) are routinely used for treating patients with metastatic renal cell cancer. However, results have been disappointing, with a majority of treatment failure. Over 6 years, the Groupe Français d’Immunothérapie enrolled 782 patients in successive multicenter trials using cytokine regimens. Univariate and multivariate analyses were performed on this large prospective database to identify prognostic factors for survival. The presence of biological signs of inflammation, short time interval from renal tumor to metastases (<1 year), elevated neutrophil counts, liver metastases, bone metastases, patient performance status (PS), the number of metastatic sites, alkaline phosphatases and hemoglobin levels were predictive of survival outcome. When compared with previous results, our study showed that PS, number of metastatic sites, disease-free interval, biological signs of inflammation and hemoglobin levels can be considered as validated prognostic factors. We also identified four independent factors predictive of rapid progression under cytokine treatment: presence of hepatic metastases, short interval from renal tumor to metastases (<1 year), more than one metastatic site and elevated neutrophil counts. Patients who combined at least three of these factors have >80% probability of rapid progression despite treatment. We think that these results must be taken into account when making the decision to treat with cytokine.
Key words: interferon, interleukin-2, metastatic renal carcinoma, prognostic factor, rapid progression, survival
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. D. Michaelson, O. Iliopoulos, D. F. McDermott, F. J. McGovern, M. G. Harisinghani, and E. Oliva Case 17-2008 -- A 63-Year-Old Man with Metastatic Renal-Cell Carcinoma N. Engl. J. Med., May 29, 2008; 358(22): 2389 - 2396. [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Vasudev, J. E. Brown, S. R. Brown, R. Rafiq, R. Morgan, P. M. Patel, D. O'Donnell, P. Harnden, M. Rogers, K. Cocks, et al. Prognostic Factors in Renal Cell Carcinoma: Association of Preoperative Sodium Concentration with Survival Clin. Cancer Res., March 15, 2008; 14(6): 1775 - 1781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. K. Rathmell, W. M. Stadler, and B. I. Rini Rational Therapeutic Choices and Strategies for Patients with Metastatic Renal Cancer ASCO Educational Book, January 1, 2008; 2008(1): 192 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska, J. Sosman, D. McDermott, I. Bodrogi, et al. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma N. Engl. J. Med., May 31, 2007; 356(22): 2271 - 2281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Schmidt, S. Suciu, C. J.A. Punt, M. Gore, W. Kruit, P. Patel, D. Lienard, H. von der Maase, A. M.M. Eggermont, and U. Keilholz Pretreatment Levels of Peripheral Neutrophils and Leukocytes As Independent Predictors of Overall Survival in Patients With American Joint Committee on Cancer Stage IV Melanoma: Results of the EORTC 18951 Biochemotherapy Trial J. Clin. Oncol., April 20, 2007; 25(12): 1562 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Choueiri, B. Rini, J. Garcia, R. Baz, R. Abou-Jawde, S. Thakkar, P Elson, T. Mekhail, M Zhou, and R. Bukowski Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma Ann. Onc., February 1, 2007; 18(2): 249 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Lam, A. Breda, A. S. Belldegrun, and R. A. Figlin Evolving Principles of Surgical Management and Prognostic Factors for Outcome in Renal Cell Carcinoma J. Clin. Oncol., December 10, 2006; 24(35): 5565 - 5575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Parton, M. Gore, and T. Eisen Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5584 - 5592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Weber, F. C. Gaertner, W. Erl, K.-P. Janssen, B. Blechert, B. Holzmann, H. Weighardt, and M. Essler IL-22-Mediated Tumor Growth Reduction Correlates with Inhibition of ERK1/2 and AKT Phosphorylation and Induction of Cell Cycle Arrest in the G2-M Phase J. Immunol., December 1, 2006; 177(11): 8266 - 8272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Donskov and H. von der Maase Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell Carcinoma J. Clin. Oncol., May 1, 2006; 24(13): 1997 - 2005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Negrier, D. Perol, C. Menetrier-Caux, J.-Y. Blay, and B. Escudier In Reply: J. Clin. Oncol., February 10, 2005; 23(5): 1044a - 1045a. [Full Text] [PDF]
|
|
|
|
|
|
T. M. Mekhail, R. M. Abou-Jawde, G. BouMerhi, S. Malhi, L. Wood, P. Elson, and R. Bukowski Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma J. Clin. Oncol., February 1, 2005; 23(4): 832 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Viey, G. Fromont, B. Escudier, Y. Morel, S. Da Rocha, S. Chouaib, and A. Caignard Phosphostim-Activated {gamma}{delta} T Cells Kill Autologous Metastatic Renal Cell Carcinoma J. Immunol., February 1, 2005; 174(3): 1338 - 1347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Michaelson, D. I. Rosenthal, and M. R. Smith Long-Term Bisphosphonate Treatment of Bone Metastases From Renal Cell Carcinoma J. Clin. Oncol., October 15, 2004; 22(20): 4233 - 4234. [Full Text] [PDF]
|
|
|
|
|
|
R. M. Bukowski, S. Negrier, and P. Elson Prognostic Factors in Patients with Advanced Renal Cell Carcinoma: Development of an International Kidney Cancer Working Group Clin. Cancer Res., September 15, 2004; 10(18): 6310S - 6314S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Negrier, D. Perol, C. Menetrier-Caux, B. Escudier, M. Pallardy, A. Ravaud, J.-Y. Douillard, C. Chevreau, C. Lasset, and J.-Y. Blay Interleukin-6, Interleukin-10, and Vascular Endothelial Growth Factor in Metastatic Renal Cell Carcinoma: Prognostic Value of Interleukin-6--From the Groupe Francais d'Immunotherapie J. Clin. Oncol., June 15, 2004; 22(12): 2371 - 2378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Motzer, J. Bacik, L. H. Schwartz, V. Reuter, P. Russo, S. Marion, and M. Mazumdar Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma J. Clin. Oncol., February 1, 2004; 22(3): 454 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Tourani, C. Pfister, N. Tubiana, M. Ouldkaci, G. Prevot, V. Lucas, S. Oudard, M. Malet, P. Cottu, J.-M. Ferrero, et al. Subcutaneous Interleukin-2 and Interferon Alfa Administration in Patients With Metastatic Renal Cell Carcinoma: Final Results of SCAPP III, a Large, Multicenter, Phase II, Nonrandomized Study With Sequential Analysis Design--The Subcutaneous Administration Propeukin Program Cooperative Group J. Clin. Oncol., November 1, 2003; 21(21): 3987 - 3994. [Abstract] [Full Text] [PDF]
|
|